14-104780214-C-A

Variant summary

Our verdict is Likely pathogenic.
+6 Likely Pathogenic
-7
-6
-1
0
+5
+6
+9
+10
B
LB
VUS
LP
P
The variant received 6 classification points (ACGS-UK Somatic Oncogenicity v2025). O3_ModerateO7_Strong

The NM_001382430.1(AKT1):c.49G>T (p.Glu17*) variant causes a stop gained, splice region change involving the alteration of a conserved nucleotide. The variant is predicted to lead to nonsense-mediated mRNA decay (NMD). The gene AKT1 is a known oncogene (CancerMine: 20 TSG, 294 oncogene, 149 driver citations). The gene AKT1 is a cancer driver gene (CancerMine: 20 TSG, 294 oncogene, 149 driver citations). The variant is absent from the gnomAD population database at sites with sufficient sequencing coverage. In-silico predictor (BayesDel (noAF)) classifies this variant as likely damaging/oncogenic. The affected nucleotide is highly conserved across species (PhyloP 100-way vertebrate score: 7.81). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar. The variant position is a cancer hotspot (cancerhotspots.org): 149 samples carry this exact amino acid change out of 298 samples with a variant at this residue. The variant has been observed in cBioPortal in 3 samples across 3 studies and 2 cancer types; somatic enrichment level: SUPPORTING_LOW (Observed in a small number of cBioPortal cases.). This exact variant is curated in the UniProt human variants database as Uncertain Significance; it is also listed as a COSMIC curated somatic variant.

Frequency

Genomes: not found (cov: 33)

Consequence

AKT1
NM_001382430.1 stop_gained, splice_region

Scores

6
1

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: 7.81

Publications

1309 publications found
Variant links:
Genes affected
AKT1 (HGNC:391): (AKT serine/threonine kinase 1) This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020]
AKT1 Gene-Disease associations (from GenCC):
  • Proteus syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), PanelApp Australia, G2P
  • Cowden disease
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Cowden syndrome 6
    Inheritance: AD, Unknown Classification: LIMITED Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), ClinGen

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_001382430.1, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACGS-UK Somatic Oncogenicity v2025

Classification was made for transcript:

Our verdict: Likely_pathogenic. The variant received 6 points.

O3Absent or very rare in population
Absent or extremely rare in gnomAD (AC ≤ 2) — O3 moderate; GnomAD: AF = absent, AC = 0 — absent/extremely rare (O3 moderate [+2])
O7Mutational hotspot or critical domain
Strong hotspot (cancerhotspots.org): >50 total samples, ≥10 same AA change; Note: exclude MSK/TCGA-derived samples from cancerhotspots count to avoid double-counting with O4; cancerhotspots.org: total samples at AA position = 298, same AA change = 149; Exclude MSK/TCGA-derived samples from count to avoid double-counting with O4; UniProt domain: 0 pathogenic, 0 benign.; ±8 AA neighbourhood: 0 pathogenic, 0 benign; No cancerhotspots.org splice hotspot hit at this position

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_001382430.1. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

AKT1 NM_001382430.1
MANE Select
HGVSc / HGVSpc.49G>Tp.Glu17*
Exon rankExon 4 of 15
stop_gainedsplice_region
Prot: NP_001369359.1UniProt: P31749-1B0LPE5
AKT1 NM_001014431.2
HGVSc / HGVSpc.49G>Tp.Glu17*
Exon rankExon 3 of 14
stop_gainedsplice_region
Prot: NP_001014431.1UniProt: B0LPE5P31749-1
AKT1 NM_001014432.2
HGVSc / HGVSpc.49G>Tp.Glu17*
Exon rankExon 4 of 15
stop_gainedsplice_region
Prot: NP_001014432.1UniProt: P31749-1B0LPE5

Ensembl Transcripts

AKT1 ENST00000649815.2
MANE Select
HGVSc / HGVSpc.49G>Tp.Glu17*
Exon rankExon 4 of 15
stop_gainedsplice_region
Prot: ENSP00000497822.1UniProt: P31749-1
AKT1 ENST00000349310.7
TSL:1
HGVSc / HGVSpc.49G>Tp.Glu17*
Exon rankExon 4 of 15
stop_gainedsplice_region
Prot: ENSP00000270202.4UniProt: P31749-1
AKT1 ENST00000402615.6
TSL:1
HGVSc / HGVSpc.49G>Tp.Glu17*
Exon rankExon 3 of 14
stop_gainedsplice_region
Prot: ENSP00000385326.2UniProt: P31749-1

Frequencies

Allele frequencies (AF), counts (AC/AN), homozygotes and coverage

Common (AF > 0.05 / Hom > 5)
Rare (AF ≤ 0.0001 / Hom ≤ 1)
Global population databases 3 sources
GnomAD3 genomes
Cov:33
GnomAD4 exome
Cov:31
GnomAD4 genome
Cov:33
Showing 3 sources

ClinVar

Not reported in ClinVar

Computational Scores

AlphaGenome AVI
Pathogenic47
BayesDel_addAF
Pathogenic0.62D
BayesDel_noAF
Pathogenic0.66
CADD
Pathogenic52
DANN
Uncertain1.0
Eigen
Pathogenic0.92
Eigen_PC
Pathogenic0.70
FATHMM_MKL
Pathogenic1.0D
GPN-Star LLR
N/A-11
GPN-Star score
N/A11
Mutation Taster
N/A6/194disease causing (fs/PTC)
PhyloP100
Pathogenic7.8
RBP_binding_hub_radar
N/A0.0
RBP_regulation_power_radar
N/A1.1
Showing 14 of 14 scores

Splicing Scores

DS_AG_spliceai
Uncertain0.26
Position offset: -3
Pangolin (max)
Uncertain0.22
Pangolin gain
Uncertain0.22
Position offset: -3
SpliceAI score (max)
Uncertain0.26
Details are displayed if max score is > 0.2
Showing 4 of 4 scores

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

MaveDB functional evidence

MaveDB is a public repository of laboratory assays that test the effect of thousands of variants at once — treat this as supporting research data and interpret it with great caution; it is not a clinical classification.

No MaveDB functional evidence found for this variant.

Publications

Other links and lift over

For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.